{"chain_id": "chain_000000", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "25891233", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 25891233, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with likelihood of abstinence when treated with nicotine in people with Tobacco Use Disorder as compared to allele G. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1051730 and nicotine in Other:Tobacco Use Disorder (PMID 25891233), what OR was reported?", "answer": "0.89", "response": "The odds ratio (OR) reported for the association between rs1051730 and likelihood of abstinence at 7 days was 1.10 (95% CIs 0.81 to 1.51), and at 28 days it was 0.89 (95% CIs 0.68 to 1.16)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000001", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "22328925", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 22328925, is the following pharmacogenomic claim supported or contradicted: Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV Infections as compared to genotypes AA + AC. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The study indicates that haplotypes carrying major alleles at IL28B, including the CC genotype of rs12979860, are associated with a higher likelihood of achieving a sustained virological response (SVR) to peginterferon alfa-2b and ribavirin therapy in HCV/HIV-1 coinfected patients."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs4803217 and peginterferon alfa-2b, ribavirin in Disease:Hepatitis C virus infection, Disease:HIV infectious disease (PMID 22328925), what p-value was reported for this association?", "answer": "= 0.000013", "response": "The p-value reported for the association of rs4803217 with sustained virological response (SVR) to peginterferon alfa-2b and ribavirin therapy in the study is 1.3\u00d710^\u22125."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000002", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "24447405", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 24447405, is the following pharmacogenomic claim supported or contradicted: Allele G is not associated with likelihood of cessation of nicotine in men with Tobacco Use Disorder as compared to allele A. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study found no significant association between the OPRM1 allele G (rs1799971) and smoking behaviors, including cessation of nicotine in men with Tobacco Use Disorder."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs2036657 and nicotine in Other:Tobacco Use Disorder (PMID 24447405)?", "answer": 146, "response": "The study did not include a control group; it only recruited 284 subjects who were current and ex-smokers with tobacco-related diseases. Therefore, there were no controls for the analysis of rs2036657 and nicotine in Tobacco Use Disorder."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "False. Since there were no controls included in the study, it does not meet the dataset minimum of N \u2265 30 for study controls."}]}
{"chain_id": "chain_000003", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "30914949", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 30914949, is the following pharmacogenomic claim supported or contradicted: Genotype CT is associated with increased risk of Alopecia due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotype TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is **contradicted**. The study indicates that the *CYP3A4* rs2740574 A/G genotype (not CT) is associated with an increased risk of alopecia, specifically in the A/G genotype compared to the A/A genotype. There is no mention of the CT genotype being linked to alopecia."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents **clinical_association**."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2740574 and bleomycin, cisplatin, etoposide in Disease:Testicular Neoplasms (PMID 30914949), what p-value was reported for this association?", "answer": "= 0.058", "response": "The reported p-value for the association of *CYP3A4* rs2740574 A/G genotype with alopecia in testicular cancer patients was **0.047**."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "**False.** The p-value of 0.047 is greater than the alpha level of 0.01, indicating that the association would not remain significant at that threshold."}]}
{"chain_id": "chain_000004", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "26699619", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26699619, is the following pharmacogenomic claim supported or contradicted: Genotype TT is associated with increased rapid virological response (rvr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The study found that the TT genotype of IFNL3 (rs8099917) was associated with higher rates of rapid virological response (RVR) compared to non-TT genotypes (GG + GT) in patients with chronic hepatitis C genotype 2/3 treated with peginterferon and ribavirin."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs8099917 and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin in Disease:Chronic hepatitis C virus infection (PMID 26699619)?", "answer": 687, "response": "A total of 687 cases were included in the study for rs8099917 in patients with chronic hepatitis C virus infection."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000005", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "32153387", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 32153387, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with risk of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to allele T. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study found no statistically significant association between the IL6 -6331T > C genotype and the risk of acute kidney rejection in tacrolimus-treated transplant recipients."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs10499563 and tacrolimus in Other:Kidney Transplantation (PMID 32153387), what confidence interval was reported?", "answer": "0.9\u20136.9", "response": "The confidence interval reported for the odds ratio of the IL6 -6331C/C genotype compared to T/T genotype in relation to acute kidney rejection was 95% confidence interval (1.7 to 25.8)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "True. The confidence interval (1.7 to 25.8) does not include the null value of 1.0."}]}
{"chain_id": "chain_000006", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "37098852", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 37098852, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with clearance of tenofovir in people with HIV Infections as compared to allele G. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study did not report any significant associations between the polymorphisms evaluated, including those that may correspond to allele A and allele G, and the clearance of tenofovir in people with HIV infections."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1800629 and tenofovir in Other:HIV infectious disease (PMID 37098852), what p-value was reported for this association?", "answer": "= 0.2", "response": "The p-value reported for the association of rs1800629 and tenofovir in the study was 0.2."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000007", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "32342502", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 32342502, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased likelihood of venous thromboembolism when treated with hormonal contraceptives for systemic use. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs6025 and hormonal contraceptives for systemic use in Toxicity (PMID 32342502)?", "answer": 487, "response": "A total of 1,777 controls were included in the study."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000008", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "18574025", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 18574025, is the following pharmacogenomic claim supported or contradicted: CYP2C9 *2 is associated with decreased dose of warfarin. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of CYP2C9*2 and warfarin in Dosage (PMID 18574025)?", "answer": 1321, "response": "The study included 1496 cases."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000009", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "21743379", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 21743379, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with exposure to lopinavir or ritonavir in children with HIV Infections as compared to allele G. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs1045642 and lopinavir, ritonavir in Other:HIV infectious disease (PMID 21743379)?", "answer": 50, "response": "The study included 50 cases."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000010", "chain_family": "B_claim\u2192presence_absence", "pmid": "40442974", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 40442974, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 40442974, rs11664064 is associated with Dosage, Toxicity outcomes for azathioprine, mercaptopurine. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 40442974 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMID 40442974 reports quantitative statistics for the claim regarding rs11664064. Specifically, it provides an odds ratio (OR) of 3.61 (p = 1.96E-8) for the BioVU cohort and an OR of 2.42 (p = 0.039) for the All of Us cohort."}]}
{"chain_id": "chain_000011", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "25350695", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 25350695, is the following pharmacogenomic claim supported or contradicted: Allele G is associated with decreased response to hmg coa reductase inhibitors as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The paper identifies that the minor allele G of the SNP rs10455872 in the LPA gene is associated with a smaller LDL-C reduction in response to statin treatment compared to the major allele A, indicating that allele G is associated with a decreased response to statins. However, the specific claim regarding \"hmg coa reductase inhibitors\" (statins) and the comparison of allele G to allele A is not directly supported in the context provided. The paper focuses on specific SNPs and their associations with LDL-C response rather than a general claim about all alleles and their effects on statin response."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs10455872 and HMG-CoA reductase inhibitors in Efficacy (PMID 25350695)?", "answer": 18075, "response": "The study included 31,056 cases for the SNP rs10455872 (LPA) in the context of HMG-CoA reductase inhibitors (statins) efficacy, as indicated in the combined analysis results."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000012", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "19901119", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 19901119, is the following pharmacogenomic claim supported or contradicted: Allele G is associated with increased risk of GI toxicity when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The study found that SNP rs4149081, which has allele G, was associated with increased gastrointestinal (GI) toxicity during methotrexate treatment, with an odds ratio indicating a significant risk."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs4149081 and methotrexate in Disease:Acute lymphoblastic leukemia (PMID 19901119)?", "answer": 434, "response": "The study included a total of 434 cases in the discovery cohort and 206 cases in the validation cohort, making a combined total of 640 cases for the analysis of rs4149081 and methotrexate in acute lymphoblastic leukemia."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000013", "chain_family": "B_claim\u2192presence_absence", "pmid": "23144877", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 23144877, is the following pharmacogenomic claim supported, contradicted, or not reported: Allele A is not associated with likelihood of Vomiting due to heroin in women with Pain, Postoperative as compared to allele G. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 23144877 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 23144877 does not report any quantitative statistics (p-value, odds ratio, or confidence interval) related to the claim about allele A and its association with vomiting due to heroin in women with postoperative pain. The study specifically focuses on the association of the SNP rs540825 with fentanyl-induced emesis, not heroin."}]}
{"chain_id": "chain_000014", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "26715213", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26715213, is the following pharmacogenomic claim supported or contradicted: Genotypes CC + CT are associated with decreased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The study found that carriers of the CYP2B6 983TC/CC genotypes had a lower risk of CNS-related adverse events compared to those with the TT genotype."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs28399499 and efavirenz in Disease:HIV infectious disease (PMID 26715213), what OR was reported?", "answer": "0.3", "response": "The odds ratio (OR) reported for the CYP2B6 983TC/CC genotype in relation to CNS-related adverse events was 0.35."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True. The confidence interval (95% CI) for the OR of 0.35 was 0.15\u20130.81, which does not include the null value of 1.0."}]}
{"chain_id": "chain_000015", "chain_family": "B_claim\u2192presence_absence", "pmid": "24433488", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 24433488, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 24433488, rs121918592 is associated with Dosage, Efficacy outcomes for desflurane, enflurane, halothane, isoflurane, sevoflurane, succinylcholine. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 24433488 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 24433488 does not report any quantitative statistics (p-value, odds ratio, or confidence interval) specifically for the claim regarding rs121918592 and its association with dosage or efficacy outcomes for desflurane, enflurane, halothane, isoflurane, sevoflurane, or succinylcholine."}]}
{"chain_id": "chain_000016", "chain_family": "B_claim\u2192presence_absence", "pmid": "26892777", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26892777, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 26892777, SLCO1B1 low activity is associated with Metabolism/PK outcomes for atazanavir. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 26892777 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 26892777 does not report any quantitative statistics (p-value, odds ratio, or confidence interval) for the claim regarding SLCO1B1 low activity and its association with metabolism or pharmacokinetic outcomes for atazanavir."}]}
{"chain_id": "chain_000017", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "23651024", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 23651024, is the following pharmacogenomic claim supported or contradicted: Genotypes CC + CT are associated with increased dose of methadone in people with Heroin Dependence as compared to genotype TT. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study indicates that carriers of two C alleles (homozygotes) of the BDNF SNP rs10835210 require relatively higher methadone doses compared to heterozygotes (CT) or non-carriers (TT)."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2289658 and methadone in Disease:Heroin Dependence (PMID 23651024), what OR was reported?", "answer": "1.592", "response": "The odds ratio (OR) reported for rs2289658 in relation to methadone dose was 1.592."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "True. The confidence interval for the OR (0.586 to 4.329) does not include the null value of 1.0."}]}
{"chain_id": "chain_000018", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "24123600", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 24123600, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The study identifies an ABCG2 haplotype (specifically the G-G haplotype) associated with increased response to imatinib, not allele C compared to allele A."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2725252 and imatinib in Disease:Chronic myelogenous leukemia, BCR-ABL1 positive (PMID 24123600), what p-value was reported for this association?", "answer": "= 0.185", "response": "The p-value reported for the association of rs2725252 with imatinib response in chronic myelogenous leukemia (CML) was 0.012 in the exploratory cohort (SLEC) and 0.047 in the 400 mg/d arm of the validation cohort (SVC)."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "False. The association would not remain significant at alpha = 0.01, as the reported p-values (0.012 and 0.047) are greater than 0.01."}]}
{"chain_id": "chain_000019", "chain_family": "B_claim\u2192presence_absence", "pmid": "7862671", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 7862671, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 7862671, TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*33, TPMT*34 is associated with Toxicity outcomes for mercaptopurine. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 7862671 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 7862671 does not report any quantitative statistics such as p-values, odds ratios (OR), or confidence intervals (CI) for the claim regarding TPMT variants and toxicity outcomes for mercaptopurine."}]}
{"chain_id": "chain_000020", "chain_family": "B_claim\u2192presence_absence", "pmid": "29705271", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 29705271, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 29705271, rs776817009 is associated with Other outcomes for o-desmethyltramadol. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 29705271 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 29705271 does not report any quantitative statistics (p-value, odds ratio, or confidence interval) for the claim regarding rs776817009 and its association with outcomes for o-desmethyltramadol."}]}
{"chain_id": "chain_000021", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "32606912", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 32606912, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with dose of sufentanil in people with Pain, Postoperative as compared to allele G. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study found no significant difference in the dosage of sufentanil associated with various SNPs, including those with allele A compared to allele G, specifically noting that the dosage of sufentanil was not significantly affected by the SNPs tested (p>0.05)."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs842647 and sufentanil in Other:Pain, Postoperative (PMID 32606912), what p-value was reported for this association?", "answer": "= 0.456", "response": "The reported p-value for the association between rs842647 and sufentanil in postoperative pain was 0.456."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "False. The p-value of 0.456 is not significant at alpha = 0.01."}]}
{"chain_id": "chain_000022", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "32451486", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 32451486, is the following pharmacogenomic claim supported or contradicted: Allele A is associated with decreased risk of Alcoholism due to ethanol as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The paper identifies risk variants associated with problematic alcohol use (PAU), but does not support the assertion that allele A is associated with decreased risk of alcoholism compared to allele G. The findings focus on identifying risk loci rather than protective alleles."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs2673136 and ethanol in Toxicity (PMID 32451486)?", "answer": 256395, "response": "The study of rs2673136 and ethanol in Toxicity included 256,395 controls."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000023", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "35150001", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 35150001, is the following pharmacogenomic claim supported or contradicted: Genotype TT is not associated with increased likelihood of Peripheral Nervous System Diseases when treated with vincristine in people with Medulloblastoma, Glioma or Brain Neoplasms as compared to genotypes CC + CT. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is **supported**. The study found no significant association between the TT genotype of CEP72 rs924607 and vincristine-induced peripheral neuropathy in the cohort of brain tumor patients, indicating that this genotype is not associated with an increased likelihood of peripheral nervous system diseases in this specific population."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents **clinical_association**."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs924607 and vincristine in Other:Medulloblastoma, Other:Glioma, Other:Brain Neoplasms (PMID 35150001), what confidence interval was reported?", "answer": "0.359\u201311.989", "response": "The confidence interval reported for the association of rs924607 and vincristine-induced peripheral neuropathy in the study was **[0.359\u201311.989]**."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "**False.** The confidence interval [0.359\u201311.989] includes the null value of 1.0, indicating that the association is not statistically significant."}]}
{"chain_id": "chain_000024", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "25744370", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 25744370, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with risk of Heroin Dependence due to heroin as compared to allele T. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is contradicted. The study found that allele C of the SNP rs3778150 is associated with an increased risk of heroin addiction, with a significant association reported (P=4.3\u00d710^\u22128)."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs647303 and heroin in Toxicity (PMID 25744370), what p-value was reported for this association?", "answer": "= 0.85", "response": "The study reported a p-value of 0.85 for the association of rs647303 with heroin addiction."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000025", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "29743634", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 29743634, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is contradicted. The study found that allele A (rs1801394 in MTRR) is associated with a poorer response to methotrexate compared to allele G, indicating that allele A is indeed associated with response to methotrexate in patients with rheumatoid arthritis."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs2847153 and methotrexate in Disease:Rheumatoid arthritis (PMID 29743634)?", "answer": 915, "response": "The study included 915 cases in the analysis of rs2847153 and methotrexate in patients with rheumatoid arthritis."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000026", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "29415147", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 29415147, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with risk of Alcoholism due to ethanol as compared to allele A. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study found that allele C (specifically in the context of SNP rs6990313) did not show a significant association with alcohol use disorder (AUD) compared to allele A, as indicated by the P-value of 0.243, which is not significant after correction for multiple comparisons."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs867858 and ethanol in Toxicity (PMID 29415147)?", "answer": 534, "response": "The study did not report any significant association for SNP rs867858 with alcohol use disorder (AUD) or ethanol toxicity, and the specific number of cases analyzed for rs867858 is not provided in the results. However, the overall number of cases with AUD in the study was 1044, but the exact count for rs867858 is not specified. Therefore, it cannot be determined from the provided information."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True. The study included a total of 1044 cases with alcohol use disorder (AUD), which exceeds the minimum dataset requirement of N \u2265 30 for study cases."}]}
{"chain_id": "chain_000027", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "24967362", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 24967362, is the following pharmacogenomic claim supported or contradicted: Genotypes AG + GG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The study focuses on the MTHFR C677T and ATIC T675C polymorphisms, and it does not mention any association with genotypes AG + GG compared to AA. Instead, it finds that the MTHFR 677TT genotype is associated with an increased risk of nonresponse to methotrexate."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs1801133 and methotrexate in Other:Rheumatoid arthritis (PMID 24967362)?", "answer": 128, "response": "The study did not include a control group; it focused solely on 233 rheumatoid arthritis patients treated with methotrexate."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "False. Since the study did not include any controls, it does not meet the dataset minimum of N \u2265 30 for study controls."}]}
{"chain_id": "chain_000028", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "21790903", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 21790903, is the following pharmacogenomic claim supported or contradicted: Genotypes GT + TT is associated with increased risk of Cocaine-Related Disorders when exposed to cocaine as compared to genotype GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is **contradicted**. The study indicates that the G allele of rs6454674 is associated with an increased risk for cocaine dependence, while the C allele of rs806368 is associated with a protective effect against cocaine dependence. The specific genotypes GT + TT for rs6454674 do not indicate an increased risk compared to GG; rather, GG is the reference genotype associated with risk."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents **clinical_association**."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs6454674 and cocaine in Other (PMID 21790903)?", "answer": 492, "response": "In the study of rs6454674 and cocaine, there were **316 controls** included."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "**True.** The dataset meets the minimum of N \u2265 30 for study controls."}]}
{"chain_id": "chain_000029", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "23278282", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 23278282, is the following pharmacogenomic claim supported or contradicted: Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The study indicates that patients with the ABCB1 genotype CT + TT did not show significantly increased metabolism of tacrolimus compared to those with genotype CC. In fact, the results suggest that the metabolite to parent concentration ratios were lower in patients with the CC genotype, indicating a more complex relationship rather than increased metabolism in the CT + TT group."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs776746 and tacrolimus in Disease:Kidney Transplantation (PMID 23278282), what p-value was reported for this association?", "answer": "< 0.024", "response": "The p-value reported for the association of rs776746 (CYP3A5 polymorphism) and tacrolimus concentrations in the study was 0.003."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000030", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "26745506", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26745506, is the following pharmacogenomic claim supported or contradicted: Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs9923231 and warfarin in Dosage (PMID 26745506), what p-value was reported for this association?", "answer": "< 0.0001", "response": "The p-value reported for the association of rs9923231 (VKORC1) with warfarin dosage in the study is p<0.001."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000031", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "26042510", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26042510, is the following pharmacogenomic claim supported or contradicted: Genotype AA is associated with increased dose of ethanol as compared to genotype AG. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs10485057 and ethanol in Dosage (PMID 26042510)?", "answer": 133, "response": "The study did not explicitly mention a separate control group for the rs10485057 polymorphism; instead, it reported genotype distributions among the entire sample of 763 participants, which included both alcohol consumers and non-consumers. Therefore, the number of controls specifically for the rs10485057 and ethanol dosage is not provided in the paper."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000032", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "21288825", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 21288825, is the following pharmacogenomic claim supported or contradicted: Genotypes AA + AG is not associated with increased discontinuation of atazanavir and ritonavir in people with HIV Infections as compared to genotype GG. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is **supported**. The study indicates that individuals with the homozygous genotype (AA) for the UGT1A1 variant had a significantly higher risk of treatment discontinuation (HR_a_ = 9.13, 95% CI: 3.38\u201324.69, P < .0001) compared to those with the GG genotype. However, the heterozygous genotype (AG) did not show a statistically significant increase in risk (HR_a_ = 1.97, 95% CI: 0.77\u20135.03, P = .158). Therefore, the genotypes AA + AG are not associated with increased discontinuation compared to GG."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents **clinical_association**."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1045642 and atazanavir, ritonavir in Disease:HIV infectious disease (PMID 21288825), what p-value was reported for this association?", "answer": "> 0.05", "response": "The reported p-value for the association of rs1045642 with atazanavir and ritonavir in the study is **0.105**."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000033", "chain_family": "B_claim\u2192presence_absence", "pmid": "26042510", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26042510, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 26042510, rs1799971 is associated with PD outcomes for nicotine. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 26042510 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 26042510 does not report any quantitative statistics (p-value, odds ratio, or confidence interval) for the claim regarding rs1799971 and nicotine outcomes. The study found no association between the rs1799971 polymorphism and the number of cigarettes or the Fagerstr\u00f6m test scores."}]}
{"chain_id": "chain_000034", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "29053440", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 29053440, is the following pharmacogenomic claim supported or contradicted: HLA-B *18:01 is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is contradicted. The study found that HLA-B *18:01* allele tended to occur more often in patients with carbamazepine-induced SJS/TEN, but statistical significance was not reached, indicating no strong association."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of HLA-B*18:01 and carbamazepine in Toxicity (PMID 29053440), what OR was reported?", "answer": "8.0", "response": "The odds ratio (OR) reported for HLA-B*18:01 in the study was 3.59 (95% CI: 1.02\u201312.66), but this was not statistically significant (p = 0.06)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "True. The confidence interval for the OR (1.02\u201312.66) does not include the null value of 1.0."}]}
{"chain_id": "chain_000035", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "26169577", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26169577, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased likelihood of Cough when treated with Ace Inhibitors, Plain as compared to allele C. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "Contradicted. The study identifies SNPs in KCNIP4 associated with ACE inhibitor-induced cough, but does not specifically mention allele T being associated with increased likelihood of cough compared to allele C. The strongest association reported is with allele A at SNP rs145489027, not T."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs7661530 and Ace Inhibitors, Plain in Other (PMID 26169577)?", "answer": 5485, "response": "In the study of rs7661530 and ACE inhibitors in the \"Other\" group, there were 123 controls included."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000036", "chain_family": "B_claim\u2192presence_absence", "pmid": "40413606", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 40413606, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 40413606, rs28929495 is associated with Dosage, Efficacy, Toxicity, Metabolism/PK outcomes for afatinib. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 40413606 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMID 40413606 reports quantitative statistics, including p-values, hazard ratios (HR), and confidence intervals (CI) for various outcomes such as time-to-treatment failure (TTF) and overall survival (OS) for patients with the EGFR-G719X mutation compared to those with other uncommon EGFR mutations. For example, it states that the median TTF for patients with G719X was 19.3 months compared to 11.2 months for others, with a hazard ratio of 0.39 (95% CI, 0.23\u20130.66; p < 0.001) for TTF. Similarly, the median OS was reported as 31.4 months for G719X versus 21.9 months for others, with a hazard ratio of 0.57 (95% CI, 0.33\u20130.98; p = 0.044)."}]}
{"chain_id": "chain_000037", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "28838926", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 28838926, is the following pharmacogenomic claim supported or contradicted: Allele A is associated with decreased metabolism of clopidogrel, enalapril and sacubitril in HEK cells as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The study identifies several nonsynonymous single nucleotide polymorphisms (nsSNPs) that are associated with decreased metabolism of clopidogrel, enalapril, and sacubitril in transfected HEK cells, indicating that specific alleles can affect the metabolic activity of CES1."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "functional_assay", "response": "The annotation represents a functional_assay."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs201065375 and clopidogrel, enalapril, sacubitril in Metabolism/PK (PMID 28838926), what p-value was reported for this association?", "answer": "< 0.001", "response": "The study does not report a specific p-value for the association of rs201065375 with the metabolism of clopidogrel, enalapril, and sacubitril. The results indicate that this variant significantly reduced CES1 protein and/or mRNA expression levels, but no exact p-value is provided in the abstract or results sections."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "False. Since no specific p-value is reported for the association of rs201065375 with the metabolism of clopidogrel, enalapril, and sacubitril, we cannot conclude that the finding is statistically significant at alpha = 0.05."}]}
{"chain_id": "chain_000038", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "24123600", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 24123600, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The study identifies an ABCG2 haplotype (specifically the G-G haplotype) associated with increased response to imatinib, but does not support the association of allele C with increased response compared to allele A."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2725252 and imatinib in Disease:Chronic myelogenous leukemia, BCR-ABL1 positive (PMID 24123600), what p-value was reported for this association?", "answer": "= 0.025", "response": "The p-value reported for the association of rs2725252 with imatinib response in chronic myelogenous leukemia (CML) was 0.012 in the exploratory cohort and 0.047 in the 400 mg/d arm of the validation cohort."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000039", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "22951632", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 22951632, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased response to efavirenz or non-nucleoside reverse transcriptase inhibitors in women with HIV Infections as compared to genotype GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The study found that the T allele at rs3745274 was significantly associated with virologic suppression, indicating that women with this allele had a higher likelihood of response to efavirenz and other non-nucleoside reverse transcriptase inhibitors compared to those with the GG genotype."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3745274 and efavirenz, non-nucleoside reverse transcriptase inhibitors in Disease:HIV infectious disease (PMID 22951632), what OR was reported?", "answer": "3.61", "response": "The odds ratio (OR) reported for rs3745274 in association with virologic suppression was 3.61 (95% CI 1.16-11.22, p trend=0.03)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True. The confidence interval (95% CI 1.16-11.22) does not include the null value of 1.0."}]}
{"chain_id": "chain_000040", "chain_family": "B_claim\u2192presence_absence", "pmid": "32004414", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 32004414, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 32004414, CYP2C9*9 is associated with Other outcomes for . Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 32004414 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 32004414 does not report any quantitative statistics (p-value, odds ratio, or confidence interval) for the claim regarding CYP2C9*9."}]}
{"chain_id": "chain_000041", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "23799528", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 23799528, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele T. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study found that the T-allele of the CNR1 rs806378 polymorphism predicted an allele dosage-dependent increase in antipsychotic-induced weight gain, indicating that allele C is not associated with increased risk compared to allele T."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs806377 and risperidone in Disease:Autism Spectrum Disorder (PMID 23799528), what p-value was reported for this association?", "answer": "= 0.17", "response": "The p-value reported for the association of rs806377 with risperidone-induced weight gain in the study was 0.17, indicating no significant association."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000042", "chain_family": "B_claim\u2192presence_absence", "pmid": "28403410", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 28403410, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 28403410, rs112563513 is associated with Metabolism/PK outcomes for caffeine. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 28403410 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 28403410 does not report any quantitative statistics (p-value, odds ratio, or confidence interval) specifically for the claim regarding rs112563513 and its association with metabolism or pharmacokinetic outcomes for caffeine."}]}
{"chain_id": "chain_000043", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "20679962", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 20679962, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with increased risk of side effects when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele T. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study found that the *IMPDH II* rs11706052 (allele T/C) SNP was not significantly associated with an increased risk of side effects or acute rejection."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs4974081 and mycophenolate mofetil in Disease:Kidney Transplantation (PMID 20679962)?", "answer": 456, "response": "The study included 456 cases for the analysis of rs4974081 and mycophenolate mofetil in kidney transplantation."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000044", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "27182616", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 27182616, is the following pharmacogenomic claim supported or contradicted: CYP2C9 *2 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of CYP2C9*1, CYP2C9*2 and warfarin in Dosage (PMID 27182616), what p-value was reported for this association?", "answer": "= 0.193", "response": "The p-value reported for the association between the mean daily ideal warfarin dose in patients with the wild-type CYP2C9*2 allele and the mean daily administered dose was <0.001."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "True."}]}
{"chain_id": "chain_000045", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "28814798", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 28814798, is the following pharmacogenomic claim supported or contradicted: Genotype CC is associated with decreased risk of Myelosuppression when treated with Platinum compounds and radiotherapy in people with Nasopharyngeal Neoplasms as compared to genotypes AA + AC. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The study indicates that the *LINC-PINT* rs1059698 CC genotype is associated with a reduced risk of myelosuppression (OR = 0.407, 95%CI = 0.180\u20130.920, P = 0.031), suggesting that CC is a protective factor, not associated with decreased risk compared to AA + AC."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1059698 and Platinum compounds, radiotherapy in Disease:Nasopharyngeal Neoplasms (PMID 28814798), what OR was reported?", "answer": "0.395", "response": "The odds ratio (OR) reported for the *LINC-PINT* rs1059698 genotype in relation to myelosuppression when treated with Platinum compounds and radiotherapy in nasopharyngeal neoplasms was 0.407 (95% CI = 0.180\u20130.920, P = 0.031)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True. The confidence interval (95% CI = 0.180\u20130.920) does not include the null value of 1.0."}]}
{"chain_id": "chain_000046", "chain_family": "B_claim\u2192presence_absence", "pmid": "22450926", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 22450926, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 22450926, rs11702425 is associated with Metabolism/PK outcomes for methotrexate. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 22450926 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 22450926 does not report any quantitative statistic (p-value/OR/CI) for the claim regarding rs11702425 being associated with Metabolism/PK outcomes for methotrexate."}]}
{"chain_id": "chain_000047", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "28049362", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 28049362, is the following pharmacogenomic claim supported or contradicted: Allele T is not associated with Blood Coagulation Disorders when treated with warfarin as compared to allele C. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study does not report any significant association between the allele T (specifically in the context of the EPHX1 c.337T>C polymorphism) and blood coagulation disorders when treated with warfarin, as it indicates no statistically significant association with warfarin dose requirement or risk of overanticoagulation for this polymorphism."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs699664 and warfarin in Efficacy, Toxicity (PMID 28049362), what p-value was reported for this association?", "answer": "= 0.5110", "response": "The study reported a p-value of .64 for the association of rs699664 (GGCX 8016G>A) with warfarin dose requirement, indicating no significant association."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000048", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "25744370", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 25744370, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with risk of Heroin Dependence due to heroin as compared to allele C. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study found that the functional SNP allele rs1799971-A was associated with heroin addiction only in the presence of rs3778150-C, indicating that allele A alone is not associated with increased risk of heroin dependence compared to allele C."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs10485060 and heroin in Toxicity (PMID 25744370), what p-value was reported for this association?", "answer": "= 0.23", "response": "The reported p-value for the association of rs10485060 with heroin addiction in the study is 0.24."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False. The p-value of 0.24 is not statistically significant at alpha = 0.05."}]}
{"chain_id": "chain_000049", "chain_family": "B_claim\u2192presence_absence", "pmid": "29027195", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 29027195, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 29027195, rs3828743 is associated with Dosage, Other outcomes for abiraterone, prednisolone. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 29027195 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMID 29027195 reports a p-value of 0.013 for the association of the TSPYL1 rs3828743 SNP variant allele (A) with worse response to abiraterone, and an odds ratio (OR) of 2.47 (1.23, 4.96) for nonresponders. Additionally, a hazard ratio (HR) of 3.36 (95% CI: 1.34\u20138.40; p = 0.01) is reported for progression-free survival (PFS) in relation to the SNP genotype."}]}
